Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y90-SIRT + Nivolumab + Ipilimumab + Lenvatinib in Unresectable HCC
NCT07482059Phase 2
Key facts
- Status
- Recruiting
- Start
- Feb 2026
- Primary completion
- Jun 2026
- Countries
- 1
- Sponsor
- West China Hospital of Sichuan University
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 microspheres, nivolumab, ipilimumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-Limiting Toxicity at 12 weeks and Objective Response Rate at 24 months. Started Feb 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Yttrium-90 microspheres + Nivolumab + Ipilimumab + Lenvatinib
Quadruple therapeutic regimen with dose exploration for ipilimumab
03
Who it enrols
Adults aged 18-80 with unresectable HCC, Child-Pugh class A, ECOG 0-1, no prior systemic therapy or TARE, adequate organ function, and no active autoimmune disease or severe comorbidities.
04
Endpoints
Primary
Dose-Limiting Toxicity
Objective Response Rate
Beyond the preview
Go deeper on NCT07482059.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482059.